Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2020-04-07 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于召集召开2019年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2019 Annual General Meeting (AGM) of Anhui Anke Biotechnology (Group) Co., Ltd. It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on, registration details, and attachments such as proxy forms and voting instructions. The document does not contain the actual annual report or financial statements but rather the announcement and procedural details for the AGM. The presence of agenda items like the 2019 annual report and financial statements being reviewed at the meeting confirms this is an AGM notice. The document length is about 5855 characters, which is consistent with a detailed AGM notice rather than a full annual report. Therefore, the correct classification is AGM Information (AGM-R).
2020-04-07 Chinese
关于2019年度计提信用减值损失及资产减值损失的公告
Regulatory Filings Classification · 90% confidence The document is an announcement by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the 2019 annual credit impairment losses and asset impairment losses. It details the reasons, amounts, and approvals related to impairment losses for the fiscal year ending December 31, 2019. The document references accounting standards and includes specific impairment testing results and approvals by the board and independent directors. It is not a full annual report but a specific announcement about impairment losses and their impact on financial results. The document length is 3761 characters, which is relatively short and focused on a specific financial adjustment rather than comprehensive financial statements or full management discussion. It is not a certification letter or a report publication announcement. Given the detailed financial impairment information and the nature of the announcement, it fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about impairment losses rather than a full financial report like an Annual Report (10-K) or Interim Report (IR).
2020-04-07 Chinese
关于获得政府补助相关情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the receipt of government subsidies. It details the amounts, sources, and accounting treatment of these subsidies for the period starting January 1, 2020, up to the announcement date. The document includes tables listing subsidy amounts and related accounting notes but does not contain comprehensive financial statements or detailed financial performance analysis. It is a regulatory announcement informing shareholders and the public about government grants received and their expected impact on profits, rather than a full financial report or earnings release. The document length is 4151 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-02 Chinese
关于非公开发行部分限售股份解除限售的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the lifting of restrictions on certain shares previously issued in a non-public offering, allowing these shares to become freely tradable on the stock exchange. It details the number of shares involved, the shareholders affected, the lock-up periods, and the dates when the shares will be released for trading. It also includes confirmations from the sponsor institution about compliance with relevant regulations. There are no financial statements, earnings data, or management discussions present. The document is a regulatory announcement about share capital changes specifically related to the release of restricted shares, which fits the category of Share Issue/Capital Change (SHA). The document length is about 4,883 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is SHA with high confidence.
2020-03-25 Chinese
国元证券股份有限公司关于公司非公开发行股票之限售股解禁上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Guoyuan Securities regarding the lifting of restrictions on non-publicly issued shares of Anhui Anke Biotechnology (Group) Co., Ltd. It includes specifics about the non-public issuance, lock-up periods, shareholders involved, share quantities, and compliance with regulatory requirements. The document is not a financial report like an annual or interim report, nor is it a simple announcement. It is a regulatory compliance and verification report related to share issuance and unlocking of restricted shares. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and verification statement rather than a financial report or announcement of voting results or capital changes. The document length is about 4909 characters, and it contains substantive content rather than just a brief announcement or certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-03-25 Chinese
关于获得药品生产注册申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the receipt of a drug production registration acceptance notice from the National Medical Products Administration (NMPA). It details the acceptance of the production registration application for a pharmaceutical product, including product information, market and R&D status, and risk warnings. The document is short (1176 characters) and serves as an official announcement of a regulatory milestone rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-03-23 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.